Skip to main content
OpenTrials
Completed

NCT Number: NCT03861780

Pilot Evaluation of Two Test Materials With a Positive Control When Used as a Patient Preoperative Skin Preparation

Comparative Study of Antimicrobial Effectiveness Evaluation of 26ml Project X, 5.1ml Project X and Prevantics Maxi Swabstick following ASTM E1173 - Standard Test Method for Evaluation of Preoperative, Precatheterization, or Preinjection Skin Preparations, ASTM International, West Conshohocken, Pennsylvania, 2015

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Bioscience Laboratories Inc

Bozeman, Montana, 59718, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects may be of either sex, at least 18 years of age, and of any race.
  • Subjects must be able to read and understand English.
  • Subjects must have read and signed an Informed Consent Form, Authorization to Use and Disclose Protected Health Information Form, and List of Restricted Products prior to participating in the study, all located in the separate Informed Consent documents.
  • Subjects must be in good general health and have no medical diagnosis of a physical condition, such as a current or recent severe illness, medicated or uncontrolled diabetes, hepatitis B, hepatitis C, an organ transplant, mitral valve prolapse with heart murmur, fibromyalgia, ulcerative colitis, Crohn's disease, an immunocompromised condition such as AIDS (or HIV positive), lupus, or medicated multiple sclerosis.
  • Subjects will have test sites on the skin of the abdomen and/or inguinal free of injury and in good condition (no active skin rashes, excessive freckling, moles, scratches, breaks in the skin, etc.) and have no currently active skin diseases or skin conditions (for example, contact dermatitis, psoriasis or eczema) that may compromise subject safety or study integrity.
  • Subjects must have skin within 6 inches of the test sites that is free of tattoos, dermatoses, abrasions, cuts, lesions or other skin disorders. Subjects with tattoos, scars, active skin rashes, or breaks in the skin of test sites, skin blemishes, such as dry scabs or warts, may be admitted at the discretion of the Principal Investigator, Subinvestigators, or Consulting Physicians.

Exclusion criteria

  • Known allergies to vinyl, latex (rubber), alcohols, metals, tapes or adhesives, inks, sunscreens, deodorants, laundry detergents, topically applied fragrances, cleansers, or to common antibacterial agents found in soaps or lotions, particularly chlorhexidine gluconate or ethanol.
  • Have experienced hives (raised welts) as a reaction to anything that contacted the skin.
  • Use of systemic or topical antibiotic medications during the 14-day pre-test period through completion of testing on the single test day.
  • Use of systemic or topical steroids, other than for contraception, hormone therapy, post-menopausal indications, during the 14-day pre-test period through completion of testing on the single test day. This includes steroid medications used to treat asthma. Note: topically applied hormonal steroids used for post-menopausal reasons must not get on the test sites.
  • Any type of port (or portacath) or Peripherally Inserted Central Catheter (PICC).
  • Pregnancy, plans to become pregnant or impregnate a sexual partner within the pre-test and test period of the study, or nursing a child. Female subjects must have a negative urine pregnancy test documented before treatment with test materials.
  • Current participation or participation in a clinical study in the past 14 days.
  • Any medical condition or use of any medications that, in the opinion of the Principal Investigator or consulting physicians, would preclude participation.

Treatment and study plan

Project X 26ml

Drug

Application of antiseptic drug to the inguinal and abdomen areas of the subjects

Project X 5.1ml

Drug

Application of antiseptic drug to the inguinal and abdomen areas of the subjects

Prevantics Maxi Swabstick

Drug

Application of antiseptic drug to the inguinal and abdomen areas of the subjects

Primary outcomes

  1. Change in Bacterial Microflora on the Inguinal Area

    Time frame: 30 seconds

    Bacterial microflora (log10) will be measured via cup scrub method administration of the intervention

  2. Change in Bacterial Microflora on the Inguinal Area

    Time frame: 10 minutes

    Bacterial microflora (log10) will be measured via cup scrub method administration of the intervention

  3. Change in Bacterial Microflora on the Inguinal Area

    Time frame: 6 hours

    Bacterial microflora (log10) will be measured via cup scrub method administration of the intervention

  4. Change in Bacterial Microflora on the Abdomen Area

    Time frame: 30 seconds

    Bacterial microflora (log10) will be measured via cup scrub method administration of the intervention

  5. Change in Bacterial Microflora on the Abdomen Area

    Time frame: 10 minutes

    Bacterial microflora (log10) will be measured via cup scrub method administration of the intervention

  6. Change in Bacterial Microflora on the Abdomen Area

    Time frame: 6 hours

    Bacterial microflora (log10) will be measured via cup scrub method administration of the intervention

Sponsors and collaborators

Lead sponsor

Professional Disposables International, Inc.

Industry

Registry information

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Mar 4, 2019
Registry last updated
Oct 22, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.